Project Grant R01ES038763
- The National Institute of Environmental Health Sciences, a division of the Department of Health and Human Services, awarded Uv01 Technologies, Inc. $306,548 under the Environmental Health program (CFDA 93.113) on August 1, 2026, to develop CLYR-VUE, an artificial intelligence and machine learning-powered just-in-time adaptive intervention that addresses indoor air pollution exposure in residential homes. The recipient will develop hardware and software infrastructure incorporating...
- The National Institute of Environmental Health Sciences awarded The Leland Stanford Junior University $699,950 on April 1, 2026, under the Environmental Health program (CFDA 93.113) to investigate cellular responses to environmentally driven replication stress. The research addresses how environmental genotoxins induce DNA lesions and stall replication forks, leading to replication stress that contributes to aging, inflammation, cancer, and chronic disease. The project focuses on replication...
- The National Institute of Environmental Health Sciences awarded Geisinger Clinic $3.379 million on September 25, 2025, under the Environmental Health program (CFDA 93.113) to characterize the relationship between extreme heat exposure and cardiovascular and pulmonary outcomes and identify health system intervention strategies in the context of climate change. The research will systematically assess how heat intensity, latency, and duration prompt or exacerbate acute events in asthma and...
- The National Institute of Environmental Health Sciences awarded The Regents of the University of California, San Francisco $117,747 on April 17, 2026, under the Environmental Health program (CFDA 93.113) to analyze the distribution, effectiveness, and implementation of wildfire smoke exposure reduction strategies and their impact on respiratory health in the San Francisco Bay Area. The project applies spatial analysis, implementation science, and exposure assessment to characterize respiratory...
- The National Institute of Environmental Health Sciences awarded The Washington University $427,625 on June 1, 2026, under the Environmental Health program (CFDA 93.113) to investigate how reactive indoor air pollutants chemically alter house dust mite allergens and enhance their capacity to trigger allergic airway inflammation. The award funds a two-aim research project examining the transformation of Der P 1 (the major house dust mite allergen), house dust mites themselves, and genuine house...
- The National Institute of Environmental Health Sciences, part of the Department of Health and Human Services, awarded $465,667 to the University of California, Los Angeles on July 1, 2026, under the Environmental Health grant program (CFDA 93.113). The award funds epidemiological research examining how pregnant women and those at conception exposed to the January 2025 Los Angeles wildfires (Pacific Palisades and Altadena fires) adopted and responded to risk mitigation strategies. The research...
- The National Institute of Environmental Health Sciences awarded Uv01 Technologies, Inc. $306,487 on July 13, 2026, under the Environmental Health program (CFDA 93.113) to develop CLYR-SIM, a personalized interactive exposure simulation tool that enables households to identify indoor air pollution sources and evaluate exposure reduction strategies specific to their homes. The Phase I project, performed in San Diego, California, runs through December 31, 2026. CLYR-SIM leverages advanced...
- The National Institute of Environmental Health Sciences awarded the University of California, Davis $749,640 in Project Grant R01ES038328 on April 1, 2026, to investigate the interplay between TET1-mediated epigenomic mechanisms and m6a RNA modification in pulmonary inflammation induced by particulate matter. The research addresses gaps in understanding how particulate matter exposure influences m6a RNA modification and its interaction with TET1 and TET1-mediated epigenomic mechanisms in...
- The National Institute of Environmental Health Sciences awarded $765,348 to the University of California, Davis on April 14, 2026, under the Environmental Health program (CFDA 93.113) to investigate pollutant-adsorbed nanoplastics and their health impacts following inhalation exposure. The research addresses the formation, distribution, and neurotoxic effects of composite particles created when airborne pollutants adsorb onto nanoplastics. The study employs advanced label-free imaging...
- Federal Project Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded UCLA a $409,687 Project Grant (CFDA 93.113, Environmental Health program) on June 24, 2025, with completion targeted for June 13, 2027. This research initiative delivers a comprehensive epidemiological investigation examining the impacts of wildfire smoke and heat exposure on cognitive decline, mood disorders, and metabolic changes in older adults with Parkinson's Disease (PD)....
The National Institute of Environmental Health Sciences awarded The Leland Stanford Junior University $850,689 on August 13, 2026, under the Environmental Health program (CFDA 93.113) to evaluate the impact of an in-home high-efficiency particulate air (HEPA) filter intervention on biological aging and cardiometabolic health markers in older adults with eosinophilic chronic obstructive pulmonary disease. The project leverages baseline and follow-up data and samples from a National Institute of Environmental Health Sciences-funded, double-blinded, randomized controlled trial placing HEPA filters versus sham filters in the homes of 178 former smokers with eosinophilic COPD for 12 months. The first aim tests whether 12-month HEPA filter intervention reduces biological aging rates in nasal epithelium and blood through epigenetic and proteomic biomarkers, hypothesizing that HEPA filtration will decrease molecular aging markers, particularly those related to cardiovascular and pulmonary aging. The second aim evaluates whether the HEPA intervention alters the epigenome, transcriptome, proteome, and cytokine profiles in blood and nasal samples, with the hypothesis that improvements in immune resilience and reductions in pro-inflammatory and pro-thrombotic pathway expressions will occur. The third aim tests whether reductions in biological aging biomarkers correlate with clinical indicators of cardiopulmonary health improvement. Performance occurs at Stanford's Palo Alto, California campus. The period of performance extends from August 13, 2026, through May 31, 2031. The assistance type is a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $850.7k | 8/13/26 |